Sandoz Group (OTCMKTS:SDZNY) Upgraded by Barclays to “Strong-Buy” Rating

Sandoz Group (OTCMKTS:SDZNY) was upgraded by Barclays from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other analysts also recently issued reports on SDZNY. Jefferies Financial Group raised Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 12th. The Goldman Sachs Group raised Sandoz Group to a “strong-buy” rating in a research note on Wednesday, April 1st. Finally, Royal Bank Of Canada downgraded Sandoz Group from a “moderate buy” rating to a “hold” rating in a research note on Monday, March 23rd. Three research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sandoz Group currently has a consensus rating of “Strong Buy”.

Sandoz Group Price Performance

Shares of SDZNY opened at $84.29 on Tuesday. Sandoz Group has a 52-week low of $44.02 and a 52-week high of $94.15. The stock has a fifty day simple moving average of $81.61 and a two-hundred day simple moving average of $76.13. The company has a quick ratio of 0.77, a current ratio of 1.18 and a debt-to-equity ratio of 0.53.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.